AIM ImmunoTech is trading at $0.20, down 5.15%, likely amid broader risk-off trading as major U.S. indices fell and rising oil prices renewed inflation and interest-rate concerns.
- No new company-specific negative catalyst was identified for September 23, 2026.
- A September 22 shareholder letter discussed Ampligen’s potential role in pancreatic cancer but did not clearly explain the decline.